...
首页> 外文期刊>Case Reports in Cardiology >Hemodynamic Support Using Percutaneous Transfemoral Impella 5.0 and Impella RP for Refractory Cardiogenic Shock
【24h】

Hemodynamic Support Using Percutaneous Transfemoral Impella 5.0 and Impella RP for Refractory Cardiogenic Shock

机译:使用经皮破碎素偶变5.0和Impella Rp进行难治性心肌休克的血流动力学支持

获取原文
           

摘要

Acute myocardial infarction (AMI) resulting in cardiogenic shock continues to be a substantial source of morbidity and mortality despite advances in recognition and treatment. Prior to the advent of percutaneous and more durable left ventricular support devices, prompt revascularization with the addition of vasopressors and inotropes were the standard of care in the management of this critical population. Recent published studies have shown that in addition to prompt revascularization, unloading of the left ventricle with the placement of the Impella percutaneous axillary flow pump can lead to improvement in mortality. Parameters such as the cardiac power output (CPO) and pulmonary artery pulsatility index (PAPi), obtained through pulmonary artery catheterization, can help ascertain the productivity of right and left ventricular function. Utilization of these parameters can provide the information necessary to escalate support to the right ventricle with the insertion of an Impella RP or the left ventricle with the insertion of larger devices, which provide more forward flow. Herein, we present a case of AMI complicated by cardiogenic shock resulting in biventricular failure treated with the percutaneous insertion of an Impella RP and Impella 5.0 utilizing invasive markers of left and right ventricular function to guide the management and escalation of care.
机译:尽管识别和治疗进展,但导致急性心肌梗死(AMI)导致心肌休克的持续性发病率和死亡率仍然是一个重要的发病率和死亡率。在经皮和更耐用的左心室支撑装置出现之前,随着添加血管和加压剂和枕形的血运重建是在这种关键人群管理中的护理标准。最近发表的研究表明,除了及时血运重建中,左心室卸下左心室的突出腋下腋窝流量泵可能导致死亡率的提高。通过肺动脉导管显示获得的心电电输出(CPO)和肺动脉脉动性指数(PAPI)等参数可以帮助确定右心室功能的生产率。这些参数的利用可以通过插入较大的器件插入较大的装置,以插入较大的装置,提供升高到右心室的右心室所需的信息。在此,我们介绍了通过心形成休克复杂的AMI的情况,导致使用左右心室功能的侵入性标记的Vembla RP和Impella 5.0治疗生物抑制失败,以指导管理和升级护理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号